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Metabolic reprogramming is a hallmark of cancer. The
changes in metabolism are adaptive to permit proliferation, sur-
vival, and eventually metastasis in a harsh environment. Stable
isotope-resolved metabolomics (SIRM) is an approach that uses
advanced approaches of NMR and mass spectrometry to analyze
the fate of individual atoms from stable isotope-enriched pre-
cursors to products to deduce metabolic pathways and net-
works. The approach can be applied to a wide range of biological
systems, including human subjects. This review focuses on the
applications of SIRM to cancer metabolism and its use in under-
standing drug actions.
Metabolism is the collection of predominantly enzyme-cat-
alyzed biochemical transformations that meet the growth and
survival demands of an organism. For nearly a century, scien-
tists have documented profound metabolic changes that occur
in tumors (1, 2). One of the earliest insights into cancer metab-
olism came when Otto Warburg noted increased uptake and
fermentation of glucose (Glc)3 to lactate in tumors relative to
surrounding tissue, even in the presence of ample oxygen (2).
Clinical cancer diagnosis exploits this “Warburg effect” by mea-
suring uptake of the Glc analogue 18F-deoxyglucose using pos-
itron emission tomography (PET), as the metabolic demands of
differentiated, non-proliferating tissues generally require far
less Glc than tumors (3).
Oncoproteins and tumor suppressors are well-established
regulators of metabolism, and mutations or dysregulated
expression can lead to the altered metabolic phenotypes
observed in many cancers (4, 5). Inactivating mutations in
enzymes such as fumarate hydratase (FH) or succinate dehy-
drogenase (SDH) induce pathophysiological accumulation of
substrates that inhibit other critical enzyme functions, whereas
less common gain-of-function mutations such as in isocitrate
dehydrogenases (IDH) produce metabolites that directly dereg-
ulate cellular processes (6). Additionally, cancer cells frequently
express fetal isoforms of metabolic enzymes that are subject to
different regulatory mechanisms to provide growth advantages
(7). Gaining a systematic understanding of the metabolic
changes that occur during carcinogenesis can thus be exploited
for therapeutic and diagnostic purposes.
Stable isotope-resolved metabolomics (SIRM) is a powerful
approach developed by others and by us where isotopically
enriched precursors such as [13C6]Glc are administered to a
biological system, and the ensuing metabolic transformations
are determined using appropriate analytic techniques to enable
robust reconstruction of metabolic pathways (8 –11). Stable
isotopes are non-radioactive and in SIRM practice are identical
chemically and functionally to the most abundant isotope of
that element. Incorporating stable isotopes such as 2H, 13C, or
15N into biological precursors has long been used to trace their
metabolism in living systems (12). SIRM is thus distinct from
non-tracer-based metabolomics profiling for statistical models.
Here, we review SIRM applications and demonstrate how it is
used to study cancer metabolism.
Analytical tools for SIRM
Mass spectrometry (MS) and nuclear magnetic resonance
(NMR) spectroscopy are the analytical tools of choice for SIRM
studies. After isotopically labeling a system and extracting the
metabolites, the number of heavy atoms (isotopologues) and
their positions (isotopomers) are determined for each metabo-
lite in crude extracts (13). As 13C has a nominal mass of 1 dalton
greater than that of 12C, MS can readily determine the number
of 13C atoms incorporated. Gas and liquid chromatography
(GC and LC) methods have been developed to resolve large
numbers of metabolites, which are often used orthogonally
with MS detection. Ultra-high-resolution MS, defined here as
m/z mass-resolving power of 350,000 (m/z 400), of which all
current models are Fourier-transform MS (UHR-FTMS), can
resolve all non-isomeric metabolites without chromatography
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(10, 14). At the sufficiently high resolution of UHR-FTMS, the
neutron m/z differences for metabolites containing 13C, 15N, or
2H can all be distinguished, allowing for multiplexed labeling
experiments. However, NMR is better suited for determining
positional labeling, e.g. to distinguish the label of [13C1]lactate
at carbon 1, 2, or 3, which are identical in molecular mass but
have distinct NMR spectral properties. 13C is magnetically
active, whereas 12C is silent thus enabling NMR to distinguish
different positions of enrichment either by direct 13C detection
or by indirect detection of the attached protons (15). Advances
in 1D and 2D NMR have enabled isotopomer analysis in com-
plex biological samples without fractionation (8). Coupling
NMR and UHR-FTMS with an atom-resolved metabolic data-
base and tracing tools can provide robust and unprecedented
reconstruction of interconnected pathways and networks (8,
10, 16, 17).
Tracer selection for interrogation of metabolic pathways
Glycolysis
Glycolysis is the metabolic pathway of NAD-dependent
oxidation of Glc to pyruvate to generate ATP and glycolytic
intermediates. [13C6]Glc is a commonly used tracer for measur-
ing glycolysis as it is relatively inexpensive and will label all
glycolytic carbons derived from Glc, and it enables tracing of
glycolysis-derived precursors in other pathways. For example,
[13C6]Glc produces the glycolytic intermediate 3-[13C3]phos-
phoglycerate, which is a substrate for purine synthesis via the
Ser-Gly one-carbon pathway (18). However, due to ambiguities
in resolving [13C3]lactate production from [13C6]Glc because of
pathways other than glycolysis, Glc tracers labeled at 13C1-2 or
13C1-3 can provide better estimation of glycolytic flux (19).
Pentose phosphate pathway
The pentose phosphate pathway (PPP) is an alternative route
for Glc metabolism, yielding ribose 5-phosphate (R5P) for
nucleotide biosynthesis and NADPH for fatty acid biosynthesis
and decomposition of peroxides (20). The choice of tracer for
analysis depends on the research question as LC-MS or ion
chromatography-MS can detect most of the PPP intermediates
(21, 22). [13C6]Glc provides maximal labeling of PPP interme-
diates as all carbons of the PPP precursors will contain labels.
However, [13C2-1,2]Glc can distinguish the oxidative and non-
oxidative branches of the PPP (Fig. 1) (23, 24). R5P isotopo-
logues containing more than one label reflect activity of both
the oxidative and non-oxidative branches of PPP as additional
13C label incorporation into R5P can only be derived through
transaldolase and transketolase activity in the non-oxidative
PPP branch (25). Furthermore, the ratio of [13C1-3]lactate to
[13C2-2,3]lactate following labeling with [13C2-1,2]Glc has been
used to estimate PPP activity in vivo (26).
Glucose G6P
NADH NADH
F6P
TK
GA3P
Lactate
CO2
Ru5P
Oxidative PPP
R5PX5P X5P
TK
TA
E4P GA3P
GA3P
+
S7P
TK GA3P
E4P
F6P
Figure 1. Production of [13C-1]ribose or [13C3-1,4,5]ribose in the oxidative or non-oxidative PPP from [
13C2-1,2]glucose. Example scheme depicting
generation of singly labeled ribose from the oxidative PPP or triply labeled ribose from the non-oxidative PPP. Glucose 6-phosphate (G6P) enters the oxidative
pentose phosphate pathway to produce M  1 ribulose 5-phosphate (Ru5P), which enters the non-oxidative branch to produce xylulose 5-phosphate (X5P)
and ribose 5-phosphate (R5P). Transketolase (TK) transfers the first two carbons of X5P to R5P to produce [13C2-1,3]sedoheptulose 7-phosphate (S7P). Transal-
dolase (TA) transfers the first three carbons from S7P to glyceraldehyde 3-phosphate (GA3P), which can be derived from glycolysis (arrow) to produce F6P. TK
then transfers two carbons from F6P to produce X5P and subsequently R5P. Note that F6P derived from X5P via TK can re-enter glycolysis to produce
[13C1-3]GA3P and subsequently [
13C1-3]lactate. Striped circles indicate labeled carbons derived from non-oxidative PPP. Other isotopomers are possible and are
not shown for simplicity. E4P, erythrose 4-phosphate.
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Krebs cycle and anaplerosis
The Krebs cycle is a central metabolic hub that integrates
carbohydrate, lipid, and amino acid metabolism. Glc, glutamine
(Gln), and fatty acids are major carbon sources that feed into
the Krebs cycle in cancer (27). [13C]Glc and -Gln are both com-
monly used tracers to label Krebs cycle intermediates via entry
as pyruvate or -ketoglutarate (-KG), respectively, producing
distinct labeling patterns. For example, pyruvate dehydroge-
nase (PDH) generates [13C2]acetyl-CoA, which condenses with
oxaloacetate (OAA) to form [13C2]- or [13C4]citrate, depending
on the first or second round of the Krebs cycle (Fig. 2A) (28). In
contrast, pyruvate carboxylase (PC) carboxylates [13C3]pyru-
vate with unlabeled CO2, generating [13C3]OAA, which con-
denses with either unlabeled or [13C2]acetyl-CoA to generate
[13C3]- or [13C5]citrate, respectively (Fig. 2A) (29, 30). Carbons
from [13C2-3,4]Glc (or [13C1-1]pyruvate) will only enter the
Krebs cycle through PC as these carbons are lost as CO2 in the
PDH reaction (Fig. 2B) (31, 32).
The choice of Gln tracer depends on the need to resolve Gln
metabolism via oxidative or reductive pathways in the Krebs
cycle. Gln undergoes glutaminolysis and enters the Krebs cycle
via -ketoglutarate (-KG) as another anaplerotic input to the
Krebs cycle (Fig. 3A). [13C5]Gln-derived -KG is then oxidized
to [13C4]succinate, -fumarate, -malate, and -OAA through the
first turn of the Krebs cycle or reduced to [13C5]citrate through
IDH-catalyzed reductive carboxylation to subsequently gener-
ate [13C3]OAA, -malate, and -fumarate (33). [13C1-1]Gln dis-
tinguishes between the two pathways because labeled products
result from reductive carboxylation as the 13C-1 label is lost as
CO2 via the -KG dehydrogenase reaction (Fig. 3B). Similarly,
[13C1-5]Gln is used to measure reductive carboxylation by trac-
ing incorporation of Gln into fatty acids as most of the label is
lost during oxidation through multiple turns of the Krebs cycle.
Furthermore, [15N]Gln allows tracing of Gln into nitrogenous
compounds such as amino acids and nucleotides (34). The uses
for common 15N and 13C tracers are summarized in Table 1.
Use of 2H in tracers requires very careful consideration of
enzyme mechanisms and chemical exchange under mostly
unknown in situ physical-chemical conditions.
SIRM profiling of cancer systems can reveal novel
metabolic reprogramming and therapeutic targets
A major goal of SIRM is to delineate the differences in sub-
strate utilization and subsequent metabolic transformations
between cancerous and non-cancerous tissues. To this end,
multiple cancer biological models have been used in SIRM
studies, including 2D and 3D cell culture, animal tumor models
derived spontaneously from defined oncogenic lesions or from
implanted tissue/cells, and human tumors analyzed in vivo or
ex vivo following surgical resection (35). Regardless of the
model, most tumors and derived cells profiled by SIRM reca-
pitulate Warburg’s original findings and disprove the canard
that tumor cells necessarily have dysfunctional mitochondria
(36) by demonstrating that Glc-derived 13C incorporation into
the Krebs cycle can be enhanced in cancerous versus paired
non-cancerous tissues (37–39). Thus, SIRM profiling is excel-
lently suited for uncovering novel aspects of cancer metabolism
in model systems and directly in human subjects.
Proliferating cells shunt Glc into pathways other than glycol-
ysis and the Krebs cycle, and SIRM has confirmed increases of
Glc flux into these pathways. For example, enhanced non-oxi-
dative and oxidative PPP activity has been reported for pancre-
atic (23) and renal (40) cancers, respectively, using a [13C2-1,2]
Glc tracer. Many cancer cells also divert Glc from glycolysis
into de novo serine synthesis and vary considerably in their de
novo serine biosynthetic capacity (18). The wide range in de
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Figure 2. 13C distribution in first turn of the Krebs cycle with [13C3]- or [lsqb]
13C1-1]pyruvate. A, [
13C3]pyruvate enters the Krebs cycle either through
pyruvate carboxylase (PC, blue circles) or pyruvate dehydrogenase (PDH, red circles). Colored circles indicate 13C label for selected metabolites. PDH-derived and
PC-derived metabolites are represented in the inner and outer circle, respectively. PC notably produces M  3 citrate, malate, and fumarate during the first turn
of the Krebs cycle, whereas PDH notably produces M  2 citrate. [13C2-2,3]Glu and [
13C2-3,4]Glu isotopomers are associated with PC and PDH activity,
respectively. B, labels from [13C-1]pyruvate (blue circle, derived from [13C2-3,4]glucose) enter the Krebs cycle exclusively through PC as the labeled carbon is lost
in the PDH reaction. Other isotopomers are possible but not shown. IDH, isocitrate dehydrogenase; GDH, glutamate dehydrogenase; GS, glutamine synthetase;
GLS, glutaminase; ME, malic enzyme; GOT, glutamic-oxaloacetic transaminase.
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novo serine biosynthesis may correlate with tumorigenic poten-
tial because the Glc to serine flux increases as cells become
progressively more tumorigenic (41). Glc carbon may also be
diverted from glycolysis for other anabolic purposes: dihy-
droxyacetone phosphate is a precursor for glycerol 3-phos-
phate used for glycerolipid synthesis (42), and fructose 6-phos-
phate (F6P) is the precursor for the hexosamine pathway
critical for protein glycosylation and intracellular regulation
(43, 44). Collectively, these reactions indicate that in many pro-
liferating cells the fraction of Glc consumed that is converted to
lactate is much less than 100%.
Many cancer cells use anaplerosis to replenish intermediates
that exit the Krebs cycle to support anabolic and/or anti-oxida-
tive demands during cell proliferation (45). For example, PC-
mediated carboxylation of pyruvate to OAA is active in several
cancers. In a non-small cell lung cancer (NSCLC) patient study,
patients receiving a bolus injection of [13C6]Glc prior to surgery
showed enhanced production of the PC-associated metabolites
[13C3]Asp, [13C3]malate, [13C3]citrate, and [13C2-2,3]Glu in
cancerous versus surrounding non-cancerous lung tissues (30,
46). Elevated PC activity was also observed in mouse orthotopic
glioblastoma (GBM) tumors after administering [13C2-3,4]Glc
(47).
Cell line studies with [13C2-1,2]Glc suggest that pyruvate flux
through PC and PDH is compartmentalized. Comparison of
[13C2-2,3]Glu (PC) to [13C2-4,5]Glu (PDH) enrichment in Jur-
kat T leukemia cells yields a ratio of about 0.4 suggesting PDH
flux is dominant in this line (25). However, the PC/PDH flux
ratio determined from [13C1-2]Glu to [13C1-4]Glu enrichment
is 30 times higher than the flux calculated from the doubly
labeled Glu species. These singly labeled isotopomers may arise
when C-1 of Glc is lost as CO2 in the oxidative PPP and re-en-
ters glycolysis as fructose 6-phosphate generated by the non-
oxidative PPP. This SIRM example demonstrates how cells with
high PPP flux may preferentially utilize the PC pathway to meet
the demands for nucleotide synthesis to support cell division.
Gln is another major anaplerotic source for Krebs cycle
replenishment and serves as a precursor in numerous meta-
bolic pathways (48). Many cancer cells appear to require Gln in
some capacity, depending on the tumor type and oncogenic
lesions (49). Cells that require Gln have characteristic 13C-la-
beling patterns with [13C6]Glc and [13C5]Gln tracers. For exam-
ple, Gln-dependent U2OS osteosarcoma cells only produce
[13C2]citrate whereas Gln-independent MCF7 breast adeno-
carcinoma cells also generate [13C6]citrate from [13C6]Glc (50).
In contrast, all 13C-isotopologues of citrate are made from
[13C5]Gln in U2OS cells confirming Gln anaplerosis in Gln-de-
pendent cells (50). These cell line differences in Gln depen-
dence are clinically relevant when studying cancer-initiating
cells (CICs), which are undifferentiated cancer cells with self-
renewal capacity and are highly resistant to conventional treat-
ments (51). In a study comparing CICs with paired, differenti-
ated cells from the same GBM tumor, CICs were much more
resistant to Gln deprivation than their differentiated controls
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Figure 3. 13C distribution in first turn of the Krebs cycle with [13C5]- or [
13C-1,5]glutamine. A, [13C5]glutamine (red circles) enters the cycle and distributes
as M  4 isotopologues through oxidative glutaminolysis (inside of cycle) or M  5 citrate through reductive carboxylation (outside of cycle). Striped dots
represent labeled carbons from [13C3]pyruvate produced via malic enzyme re-entering the Krebs cycle. For simplicity, not all isotopologues are shown, and the
re-entry of labeled pyruvate into the Krebs cycle could produce the same isotopologues as in Fig. 2A. B, labels from [13C-1]Gln (red circles) are lost following
decarboxylation of C-1 by -KG dehydrogenase. The 13C label is retained in citrate through the reverse reaction of IDH but is not incorporated into fatty acids.
The label from [13C-5]Gln (blue circle) is retained through glutaminolysis but is only incorporated into fatty acids via reductive carboxylation.
Table 1
Common stable-isotope tracers and their uses
Tracer Labeled pathway Ref.
[U-13C]Glucose Glycolysis, PPP, Krebs cycle, hexosamine,
nucleotide, lipid synthesis
22, 30
[1,2-13C]Glucose Non-oxidative versus oxidative PPP 23, 24
[3,4-13C]Glucose PC anaplerosis 31, 32
[13C/15N]Glucose Glutaminolysis, nucleotide biosynthesis,
Krebs cycle, and fatty acid synthesis
30, 39, 58
13C-Labeled fatty acids -Oxidation, fatty acid synthesis 97
[13C]Serine Serine metabolism, one-carbon
metabolism, lipid synthesis
98
[13C]Glycerol Lipid synthesis, gluconeogenesis-pentose
cycle interactions
99, 100
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(52). This may be related to a higher capacity for [15N]Gln syn-
thesis from 15NH4 in CICs than differentiated cells (52).
Given the heterogeneity in Gln requirements between cancer
cell lines and even cells within the same tumor, several studies
have profiled tumors in vivo to establish Glc and Gln depen-
dences. Cell lines derived from KRASG12D;TP53/-induced
mouse adenocarcinomas avidly consume Gln and are sensitive
to glutaminase (GLS) inhibitors in vitro (53). However, xeno-
grafts from these cells were insensitive to GLS inhibition. Sim-
ilarly, 13C labeling was higher in mouse orthotopic human
GBM tumors following injection of [13C]Glc compared with
[13C]Gln, suggesting that these tumors use less Gln in vivo
(53). Tumors resected following [13C6]Glc infusion produce
[13C3]citrate, -malate, and -aspartate, which is consistent with
active PC, suggesting that both routes of anaplerosis are utilized
by tumors depending on nutrient availability (30, 37, 46). These
studies also suggest that metabolic alterations occur during
adaptation to cell culture and/or that the tumor microenviron-
ment substantially influences tumor metabolism (53).
Cancer cells synthesize lipids de novo to meet growth
requirements (54), and we now appreciate that Gln carbons can
fuel citrate and subsequent lipid biosynthesis through oxidative
glutaminolysis or reductive carboxylation in the Krebs cycle.
In the oxidative pathway, Gln-derived OAA condenses with
acetyl-CoA to produce citrate as precursor to fatty acid biosyn-
thesis. Alternatively, malic enzyme can convert Gln-derived
malate to pyruvate, which then re-enters the Krebs cycle and
generates acetyl-CoA via PDH (Fig. 2A). Certain conditions,
such as hypoxia, inhibit PDH activity leading to reduced acetyl-
CoA production from pyruvate (55). These conditions favor
carboxylation of Gln-derived -KG by the reverse reaction of
IDH to generate citrate (Fig. 3B) (56, 57). For example, Gln-de-
pendent GBM cells produce [13C4]fumarate, -malate, and -cit-
rate when traced with [13C5]Gln under normoxia. However,
hypoxia induces a shift to [13C5]citrate synthesis (56). [13C1-1]
Gln tracing has confirmed reductive carboxylation in cell lines
derived from lung, breast, melanoma, and colon cancers (57)
and from cells with mitochondrial deficiencies in FH (58) or
SDH (59). Reductive carboxylation also occurs in in vivo as
evidenced by [13C]citrate production in mouse tumors follow-
ing injection of [13C1-1]Gln (60).
Nutrient availability may significantly contribute to the met-
abolic plasticity in tumors. When mice bearing NSCLC tumors
were injected with [13C1-2]lactate, 13C1-isotopologues of glyco-
lytic and Krebs cycle intermediates were detected in these
tumors suggesting lactate-derived pyruvate entered the Krebs
cycle or the gluconeogenic pathway (37). NSCLC and breast
cancer cells consume [13C3]lactate or [13C5]Gln to produce
13C-labeled glycolytic intermediates and [13C]serine through
the key gluconeogenic enzyme phosphoenolpyruvate carboxy-
kinase 2, and gluconeogenic activity is enhanced under Glc
withdrawal (61, 62). Tumors can also consume acetate, and in
mice bearing human orthotopic GBM tumors, infusion of
[13C2,1,2]acetate produces [13C2,4,5]Glu suggesting that exog-
enous acetate can fuel the Krebs cycle (63). [13C2,1,2]Acetate
oxidation has also been detected in human GBM tumors after
resection, and GBMs consume [11C]acetate in vivo as measured
by PET (63).
SIRM can elucidate downstream effects of oncogene
activation
SIRM has been used to characterize some of the key meta-
bolic alterations resulting from oncogenic lesions.
RAS
RAS proto-oncogenes are among the most frequently
mutated oncogenes in human cancers (64). Oncogenic KRAS
decouples glycolysis and the Krebs cycle by increasing Glc
uptake and conversion to lactate while decreasing Glc entry
into the Krebs cycle in fibroblasts (65, 66) and in cells derived
from mice with KRAS-driven spontaneous tumor formation
(53). Tracing by [13C2-1,2]Glc shows that oncogenic KRAS
increases flux into the PPP, presumably to fuel nucleotide bio-
synthesis (21, 66). KRAS-driven cancer cells also require Gln for
proliferation, although this requirement depends largely on
extracellular environment (53) or specific mutation (67). Onco-
genic KRAS increases production of [13C4]aspartate from
[13C5]Gln (65), which can be transported into the cytoplasm
and converted to OAA via cytosolic aspartate transaminase
(68). The subsequent conversion to malate and pyruvate by
malate dehydrogenase and malic enzyme increases NADPH to
maintain cellular redox state. In contrast, HRASG12V transfor-
mation of immortalized epithelial cells increases [13C]Glc entry
into the Krebs cycle and sensitizes the cells to mitochondrial
inhibitors (69). These studies suggest that the RAS family mem-
bers may transform cells by differentially reprogramming met-
abolic pathways.
MYC
The MYC transcription factor is frequently overexpressed in
human cancers (70) and regulates the expression of many met-
abolic enzymes (71). Mice transgenic for MYC overexpression
in liver develop sporadic hepatocellular carcinomas (72) that
show increased [13C]Glc uptake and subsequent production of
[13C]lactate relative to normal adjacent tissue due to glycolytic
gene induction by MYC (49), which agrees with the effects of
MYC overexpression in B cells (73). In carcinomas, MYC also
drives increased [13C]Gln uptake and conversion to [13C]Glu by
inducing glutamine transporters and GLS expression, leading
to increased 13C labeling of Krebs cycle intermediates and
increased Gln incorporation in lactate (4, 49, 74). In a MYC-
driven hepatocellular carcinoma model using hyperpolarized
[13C]pyruvate, [13C]lactate was the main product, but in pre-
cancerous regions [13C]alanine was produced, a phenotype not
found in normal or tumor tissues (75). Thus, SIRM led to iden-
tification of alanine aminotransferase as a potential early
marker of MYC-induced carcinogenesis. Interestingly, hepato-
cellular carcinoma models driven by a different oncogene,
MET, failed to phenocopy the MYC-driven metabolic pertur-
bations suggesting that metabolic reprogramming differs based
on oncogenic lesions (49).
Retinoblastoma protein
The retinoblastoma protein (pRb) is a tumor suppressor that
restricts passage from G1 into S phase during the cell cycle, and
pRb is functionally inactivated in most cancers (76). Unlike
oncogenic KRAS, increased [13C]Glc uptake and lactate pro-
MINIREVIEW: SIRM and cancer metabolism
J. Biol. Chem. (2017) 292(28) 11601–11609 11605
duction was not observed in tissues derived from RB knock-out
mice or RB-silenced epithelial cells (77). Instead, loss of pRb
enhances Glc entry into the Krebs cycle, as evidenced by an
increase in PDH-mediated production of [13C2]citrate (77).
Loss of pRb more profoundly impacts Gln metabolism as Gln
uptake and conversion to Glu were activated in mouse embry-
onic fibroblasts derived from RB knock-out mice (78). The
most striking effect of pRb knock-out is increased 13C labeling
of glutathione derived from [13C5]Gln (78, 79). These results
suggest that the metabolic role of pRb may be to divert Gln
carbons to anti-oxidative pathways that control reactive oxygen
species accumulation during cell cycle progression.
Applications of SIRM in drug development
Many clinically successful drugs or promising drug candi-
dates may benefit from SIRM analyses to gain insights into
their molecular mechanisms. For example, SIRM implicated
enhanced glycolysis and PC-mediated Krebs cycle activity in
the mechanism of the anti-manic depression drug lithium on
neurons and astrocytes (28). Likewise, selenium agents per-
turbed Krebs cycle activity and attenuated lipid biosynthesis in
lung cancer cells, and these alterations were related to an acti-
vation of the AMP–AMP kinase pathway as was determined by
SIRM and microarray experiments (80). Anti-cancer target dis-
covery is one of the most promising translational applications
for SIRM, and inhibitors of several targets have been developed
and are showing promise in preclinical models (81). These
inhibitors can also potentiate the efficacy of conventional che-
motherapeutics (82).
Metabolic enzymes are frequently mutated in certain cancers
such as SDH in gastrointestinal, renal cell carcinomas, and
paraganglioma tumors (83), IDH in GBM (84), and FH in renal
cell cancers (85). These mutations often result in the produc-
tion of excess “oncometabolites” that promote activation of
proliferative transcription factors and regulate DNA methyla-
tion (6). Tracer studies show that SDH-null cells produce cit-
rate predominantly through reductive carboxylation of Gln and
accumulate Gln-derived succinate, a product inhibitor of the
-KG-dependent dioxygenases, while relying on PC for anaple-
rosis and synthesis of aspartate to support nucleotide biosyn-
thesis required for proliferation (59, 86, 87). Likewise, IDH1
mutant cells increased conversion of [13C1-2]Glc to PC-derived
[13C1-3]Glu, which implicates the importance of PC anaplero-
sis for proliferation of these cells (88). More intriguingly, PC
expression and in vivo activity were enhanced in human
NSCLC tumors relative to adjacent non-cancerous lung tissues,
and silencing PC expression in lung cancer lines slowed tumor
growth in mouse xenografts (8, 53). Together, these results sug-
gest that PC may be a viable drug target for certain types of
cancer. Furthermore, [13C]Gln profiling of WT versus FH-null
mice revealed a dramatic increase in [13C4]arginosuccinate, a
urea cycle intermediate that is normally converted to fumarate
and arginine by arginosuccinate lyase (ASL) (89). This accumu-
lation of labeled arginosuccinate can be attributed to elevated
fumarate levels in FH-null cells to drive the reverse reaction of
ASL and deplete the cells of arginine, rendering them auxotro-
phic for arginine. Enzymatic depletion of arginine prevented
cell proliferation, thus demonstrating the utility of targeting
this system in FH-deficient cells (89).
SIRM may also be applied to cancer therapeutics by investi-
gating the mechanisms of drug resistance. For example, ima-
tinib treatment of chronic myeloid leukemia cells induces a
shift from glycolysis to mitochondrial metabolism, a phenotype
associated with non-cancerous tissues (90, 91). Imatinib-resist-
ant cells display no such decrease in glycolysis in response to
drug treatment. In addition, cells switched from the oxidative
to non-oxidative PPP for ribose production as they became
resistant to imatinib (91). Thus, screening cells from patients
for these metabolic avoidance traits may predict their sensitiv-
ity to imatinib treatment.
As discussed previously, cell-based tracer experiments may
not always reflect in vivo tumor metabolism, and target discov-
ery in more relevant model systems is necessary (35). In a study
comparing pancreatic CIC spheres with adherent, differenti-
ated cells from the same tumor, the CICs showed less Glc flux
into lactate and ribose via glycolysis and the PPP, respectively,
and more flux into the Krebs cycle (92). Likewise, CICs were
more susceptible to mitochondrial inhibitors than differenti-
ated cells, and resistant clones were shown to have a mixed
phenotype. By genetically and pharmacologically manipulating
factors that regulate mitochondrial biogenesis, resistant CICs
became sensitive to mitochondrial inhibitors (92). Thus, under-
standing the metabolic basis of chemotherapy resistance in rel-
evant model systems will certainly facilitate more robust target
identification for improving therapeutic outcomes.
Concluding remarks/future directions
SIRM profiling has unveiled the complex and plastic nature
of cancer metabolism. Tumors are highly adaptable to changing
nutrient supplies, which creates conceptual and technical
research challenges that may not be met with commonly used
model systems. For example, recent studies have demonstrated
the importance of the microenvironment for tumor metabo-
lism either through immune modulation (22) or through direct
regulation by stromal cells (93). Our group has demonstrated
that ex vivo cultured tumor slices from primary tumors are via-
ble metabolically and immunologically with the maintenance of
the 3D tumor architecture and microenvironment (22, 30, 39,
94). These ex vivo slices provide the unique opportunity to
study the effects of environmental variants or drug treatment
on metabolic networks directly in human tumors without sys-
temic complications. As such, this new approach can circum-
vent the long-standing concerns for cell or animal models in
recapitulating human tumor metabolism.
SIRM highly complements other “omic” profiling technolo-
gies already being practiced clinically. By gaining insights into
metabolic dysfunction due to cancer development or drug
interventions, SIRM-generated knowledge can be integrated
with genomic and proteomic information to achieve systems
biochemical insights in both model systems and individual
human patients. SIRM can further promote discovery of mech-
anism-based biomarkers for early detection and prediction of
drug responses. Metabolite profiling for statistical modeling
has identified potential biomarkers for cancers such as lung (95)
and cervix (96), but the etiology of these biomarkers is mostly
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unknown. SIRM investigations can unambiguously trace the
pathway(s) from which such biomarkers are derived and accel-
erate the mapping of specific pathway dysregulations derived
from other ‘omics information. This knowledge is pivotal for
translating biomarker candidates into clinical practices. We
believe the future of cancer research and treatment will greatly
benefit from SIRM as more researchers adapt this technology
and contribute to the growing atlas of reprogrammed cancer
metabolism.
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